Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 4055

1.

Management of gastrointestinal bleeding in patients anticoagulated with dabigatran compared with warfarin: a retrospective, comparative case review.

Manatsathit W, Al-Hamid H, Leelasinjaroen P, Hashmi U, McCullough PA.

Cardiovasc Diagn Ther. 2014 Jun;4(3):224-31. doi: 10.3978/j.issn.2223-3652.2014.03.07.

PMID:
25009791
[PubMed]
2.

Meta-Analysis of the Influence of Chronic Kidney Disease on the Risk of Thromboembolism Among Patients With Nonvalvular Atrial Fibrillation.

Providência R, Marijon E, Boveda S, Barra S, Narayanan K, Le Heuzey JY, Gersh BJ, Gonçalves L.

Am J Cardiol. 2014 Jun 6. pii: S0002-9149(14)01241-7. doi: 10.1016/j.amjcard.2014.05.048. [Epub ahead of print] Review.

PMID:
25001152
[PubMed - as supplied by publisher]
3.

Effect of Selective Serotonin Reuptake Inhibitors on Bleeding Risk in Patients With Atrial Fibrillation Taking Warfarin.

Quinn GR, Singer DE, Chang Y, Go AS, Borowsky LH, Udaltsova N, Fang MC.

Am J Cardiol. 2014 Jun 5. pii: S0002-9149(14)01230-2. doi: 10.1016/j.amjcard.2014.05.037. [Epub ahead of print]

PMID:
25001151
[PubMed - as supplied by publisher]
4.

Anticoagulation-related reduction of first-ever stroke severity in Chinese patients with atrial fibrillation.

Wang C, Wang Y, Wang C, Zhao X, Liu L, Liu G, Wang DZ, Li H, Wang Y.

J Clin Neurosci. 2014 Jul 3. pii: S0967-5868(14)00190-8. doi: 10.1016/j.jocn.2014.01.022. [Epub ahead of print]

PMID:
24998862
[PubMed - as supplied by publisher]
5.

Prospective Randomized Evaluation of the Watchman Left Atrial Appendage Closure Device in Patients With Atrial Fibrillation Versus Long-Term Warfarin Therapy: The PREVAIL Trial.

Holmes DR Jr, Kar S, Price MJ, Whisenant B, Sievert H, Doshi SK, Huber K, Reddy VY.

J Am Coll Cardiol. 2014 Jul 8;64(1):1-12. doi: 10.1016/j.jacc.2014.04.029.

PMID:
24998121
[PubMed - in process]
6.

Meta-Analysis of Efficacy and Safety of Rivaroxaban Compared With Warfarin or Dabigatran in Patients Undergoing Catheter Ablation for Atrial Fibrillation.

Aryal MR, Ukaigwe A, Pandit A, Karmacharya P, Pradhan R, Mainali NR, Pathak R, Jalota L, Bhandari Y, Donato A.

Am J Cardiol. 2014 Jun 6. pii: S0002-9149(14)01231-4. doi: 10.1016/j.amjcard.2014.05.038. [Epub ahead of print]

PMID:
24998087
[PubMed - as supplied by publisher]
7.

Treatment Discontinuations With New Oral Agents for Long-term Anticoagulation: Insights From a Meta-analysis of 18 Randomized Trials Including 101,801 Patients.

Chatterjee S, Sardar P, Giri JS, Ghosh J, Mukherjee D.

Mayo Clin Proc. 2014 Jul;89(7):896-907. doi: 10.1016/j.mayocp.2014.01.030.

PMID:
24996233
[PubMed - in process]
8.

Intracranial Hemorrhage Mortality in Atrial Fibrillation Patients Treated With Dabigatran or Warfarin.

Alonso A, Bengtson LG, MacLehose RF, Lutsey PL, Chen LY, Lakshminarayan K.

Stroke. 2014 Jul 3. pii: STROKEAHA.114.006016. [Epub ahead of print]

PMID:
24994722
[PubMed - as supplied by publisher]
9.

NOAC in Acute Coronary Syndrome and AF?

Niespialowska-Steuden M, Collins P, Costopoulos C, Gorog DA.

Cardiovasc Hematol Disord Drug Targets. 2014 Jun 30. [Epub ahead of print]

PMID:
24993123
[PubMed - as supplied by publisher]
10.

Graves' disease and treatment effects on warfarin anticoagulation.

Howard-Thompson A, Luckey A, George C, Choby BA, Self TH.

Case Rep Med. 2014;2014:292468. doi: 10.1155/2014/292468. Epub 2014 Jun 4.

PMID:
24991217
[PubMed]
Free PMC Article
11.

Comparing Mortality in Patients with Atrial Fibrillation who are Receiving a Direct Oral Anticoagulant or Warfarin: A Meta-analysis of Randomized Trials.

Liew A, O'Donnell M, Douketis J.

J Thromb Haemost. 2014 Jul 1. doi: 10.1111/jth.12651. [Epub ahead of print]

PMID:
24986568
[PubMed - as supplied by publisher]
12.

[Practical questions on therapy with new antithrombotic agents].

Vojáček J.

Vnitr Lek. 2014 Apr;60(4):389-95. Czech.

PMID:
24986003
[PubMed - in process]
13.

Antithrombin levels are unaffected by warfarin use.

Sanfelippo MJ, Engel JM, Onitilo AA.

Arch Pathol Lab Med. 2014 Jul;138(7):967-8. doi: 10.5858/arpa.2013-0065-OA.

PMID:
24979180
[PubMed - in process]
14.

Atrial fibrillation and quality of life related to disease and treatment: focus on anticoagulation.

Ynsaurriaga FA, Peinado RP, Ormaetxe Merodio JM.

Future Cardiol. 2014 May;10(3):381-93. doi: 10.2217/fca.14.13.

PMID:
24976475
[PubMed - in process]
15.

Inappropriate Use of Oral Anticoagulants for Patients With Atrial Fibrillation.

Akao M, Chun YH, Esato M, Abe M, Tsuji H, Wada H, Hasegawa K.

Circ J. 2014 Jun 27. [Epub ahead of print]

PMID:
24976391
[PubMed - as supplied by publisher]
Free Article
16.

Target-specific oral anticoagulants in patients undergoing cardioversion.

Law EH, Gordon W.

Am J Health Syst Pharm. 2014 Jul 15;71(14):1171-6. doi: 10.2146/ajhp130548.

PMID:
24973374
[PubMed - in process]
17.

Cost-effectiveness of dabigatran versus vitamin K antagonists for the prevention of stroke in patients with atrial fibrillation: A French payer perspective.

Chevalier J, Delaitre O, Hammès F, de Pouvourville G.

Arch Cardiovasc Dis. 2014 Jun 24. pii: S1875-2136(14)00103-X. doi: 10.1016/j.acvd.2014.04.009. [Epub ahead of print]

PMID:
24973113
[PubMed - as supplied by publisher]
18.

Edoxaban versus warfarin for stroke prevention in non-valvular atrial fibrillation: a cost-effectiveness analysis.

Rognoni C, Marchetti M, Quaglini S, Liberato NL.

J Thromb Thrombolysis. 2014 Jun 28. [Epub ahead of print]

PMID:
24973057
[PubMed - as supplied by publisher]
19.

Stroke prevention in atrial fibrillation--current standard of care and significant unmet medical need.

Vora A, Narasimhan C.

J Assoc Physicians India. 2013 Dec;61(12):904-6.

PMID:
24968548
[PubMed - in process]
20.

Dabigatran etexilate in atrial fibrillation.

Vora A.

J Assoc Physicians India. 2013 Dec;61(12):900-2.

PMID:
24968547
[PubMed - in process]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk